ALGORITHM FOR STRATIFICATION OF WOMEN FOR DIFFERENTIATED THERAPY OF MENOPAUSAL SYNDROME IN COMBINATION WITH PERIMENOPAUSAL MELATONIN DEFICIENCY SYNDROME

2021 ◽  
pp. 1137-1141
Author(s):  
А. Г. Мамонтова ◽  
Е. Н. Усольцева ◽  
А. Г. Соловьев
Keyword(s):  
Combined Treatment ◽  
Bodily Pain ◽  
Deficiency Syndrome ◽  
Active Ageing ◽  
Menopausal Syndrome ◽  
Menopausal Women ◽  
Life Improvement ◽  
Post Menopausal ◽  
Selection Of

Климактерический синдром (КС) является ведущим проявлением патологического климактерия. Наряду с дефицитом половых стероидов, при КС наблюдают изменение синтеза гормона эпифиза мелатонина (МТ), что приводит к формированию синдрома перименопаузального дефицита мелатонина (СПДМ) - симптомокомплекса, клинически характеризующегося доминированием жалоб на нарушение сна, болевые ощущения в теле, а также наличием депрессии, тревоги/страхов и соматических симптомов. КС и СПДМ являются коморбидными состояниями, нарушающими климактерическое здоровье женщин. Представлен алгоритм стратификации женщин в пери-и постменопаузе с КС и СПДМ для подбора дифференцированной терапии, включающий определение показаний к монотерапии препаратами МТ, синтетического гинестеина, а также к сочетанному лечению с менопазульной гормональной терапией. Обосновано применение предложенного подхода для повышения эффективности терапии КС в сочетании с СПДМ, улучшения показателей качества жизни и стимулирования здорового и активного долголетия женщин старшей возрастной группы. Climacteric syndrome (CS) is considered to be a frequent manifestation of pathological menopause. Menopause associated not only with deficiency of sex steroids, decrease of melatonin secretion is observed. Perimenopausal melatonin deficiency syndrome (SPDM) is the complex of symptoms, which is often formed amid decrease of melatonin synthesis and clinically characterized by the prevalence of complaints of sleep disorders (problems), bodily pain, depression, anxiety/fears and somatic symptoms. CS and SPD are co-morbidities, that impair the «women menopausal health». The article presents the stratification algorithm of peri- and post-menopausal women with the co-morbid pathology of CS and SPDM for selection of differentiated therapy. The algorithm involves detection of indications for monotherapy with melatonin or synthetic genistein, and for combined treatment with menopausal hormone therapy. The usage of this concept is reasonable for improvement of treatment efficiency of co-morbid pathology of CS and SPDM, for quality of life improvement and for induction of active ageing of women of senior group.

scholarly journals QUALITY OF LIFE CHANGES IN POST-MENOPAUSAL WOMEN WITH OSTEOPOROSIS AFTER SHORT TERM TAI CHI EXERCISE PROGRAM

2018 ◽  
Vol 28 (2) ◽  
pp. 114-117
Author(s):  
Ema Lašinytė ◽  
Kristina Berškienė ◽  
Vilma Mauricienė
Keyword(s):  
Quality Of Life ◽  
Tai Chi ◽  
Bodily Pain ◽  
Exercise Program ◽  
Life Changes ◽  
Sf 36 ◽  
Menopausal Women ◽  
Tai Chi Exercise ◽  
Post Menopausal

Objectives. To evaluate quality of life changes in post-menopausal women with osteoporosis after application of Tai Chi exercise program. Material and methods. 13 post-menopausal women with osteoporosis participated in the study which included application of Tai Chi exercise program for eight weeks. Two, one-hour group training sessions were taught per week. Quality of life was assessed two times: before and after eight weeks of Tai Chi program. Quality of life measurements were conducted using SF-36 questionnaire. Results. Research data showed statistically significant changes (p<.05) in three of eight SF-36 fields after application of Tai Chi exercise program: bodily pain, general health perception and emotional role functioning while no significant changes were observed in other five fields (p≥ .05). Conclusions. Obtained results showed positive changes in Physical and Mental component areas. However, further future research is still needed to find out how Tai Chi program would affect other fields of the life.

scholarly journals Associations of Erythrocyte Polyunsaturated Fatty Acids with Inflammation and Quality of Life in Post-Menopausal Women with Obesity Completing a Pilot Dietary Intervention

Nutrients ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1589
Author(s):  
Kylie M. Johnson ◽  
Kellie R. Weinhold ◽  
Rebecca Andridge ◽  
Kristen Arnold ◽  
Panchita P. Chu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Dietary Intervention ◽  
Short Form ◽  
Omega 3 ◽  
Markers Of Inflammation ◽  
Menopausal Women ◽  
Post Menopausal

Study objectives were to determine if erythrocyte omega-3 polyunsaturated fatty acids (n-3 PUFAs) increased in women participating in a dietary intervention that reduced inflammation and body weight and examine PUFA associations with markers of inflammation and quality of life (QOL). An experimental pre-post test, single group design was used. Fifteen post-menopausal women with obesity were enrolled in a 12-week pilot intervention focusing on lowering added sugars and increasing fiber and fish rich in n-3 PUFAs. Measurements included fasting blood samples, anthropometric, lifestyle and dietary data collected at baseline, end of intervention (Week 12) and follow-up (Week 24). Primary outcomes were change in erythrocyte PUFAs and associations between erythrocyte PUFAs, QOL (Short Form 12), and inflammatory markers (interleukin-6, tumor necrosis factor-α-receptor 2, and high sensitivity C-reactive protein (CRP)). Fourteen women completed all intervention visits. Mean erythrocyte docosahexaenoic acid and arachidonic acid (AA) increased at Week 12 and Week 24 (p < 0.001 for both), while eicosapentaenoic acid increased at Week 24 (p < 0.01). After adjustment for percent weight change, week 12 QOL related to physical function was significantly associated with erythrocyte linoleic acid (p < 0.05) and trended toward significant association with EPA (p = 0.051); week 24 CRP was directly associated with erythrocyte AA (p < 0.05). Erythrocyte n-3 PUFAs were not associated with inflammation.

scholarly journals OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
James Simon ◽  
Richard A Anderson ◽  
Elizabeth Ballantyne ◽  
Hadine Joffe ◽  
Mary Kerr ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Dose Finding ◽  
Vasomotor Symptoms ◽  
Phase 3 ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Menopausal Women ◽  
Post Menopausal

Abstract Introduction: Vasomotor symptoms (VMS), caused by declining estrogen in menopausal women, are common and debilitating. Hormone therapy is effective in many women but carries risks and may be contraindicated. Biological and clinical evidence shows a modulatory role for neurokinin (NK) receptor antagonists acting primarily via hypothalamic KNDy (kisspeptin, NK, dynorphin) neurons on VMS. NT-814 is an oral non-hormonal dual NK1,3 receptor antagonist which has previously been shown to cause rapid and marked improvements in VMS in post-menopausal women. This Phase-2b trial (SWITCH-1) was undertaken to further evaluate efficacy and safety and to establish the optimum dose(s) for Phase 3 studies. Methods: SWITCH-1 was a double-blind, placebo-controlled, adaptive-randomization, dose-finding trial in 199 post-menopausal women. After a 2-week single-blind placebo run-in to establish symptom stability, women (40 to 65 years) with ≥7 moderate and/or severe VMS per day at baseline were randomized to 12 weeks of once daily treatment with placebo or one of 4 doses of NT-814: 40 mg, 80 mg, 120 mg, 160 mg. Subjects recorded the frequency and severity of VMS in electronic diaries twice daily throughout the study. Patient-reported measures of quality-of-life, sleep and mood were collected periodically. Adverse events (AEs) were recorded at each clinic visit. Results: VMS frequency was reduced in all treatment groups, including placebo. VMS reductions were significantly greater with the 2 higher NT-814 doses at most time-points, as early as the first week of treatment. Least squares mean reductions from baseline in moderate/severe VMS per day at week 4 were: placebo, 2.7; 40 mg, 4.3 (p=0.161 vs placebo); 80 mg, 4.1 (p=0.326); 120 mg, 6.7 (p&lt;0.0001); 160 mg, 5.5 (p=0.007). In week 12 the reductions were: placebo, 4.7; 40 mg, 6.5 (p=0.185); 80 mg, 5.6 (p=0.599); 120 mg, 7.8 (p=0.009); 160 mg, 6.6 (p=0.109). At the 160 mg dose the median reduction in week 12 was significantly greater than placebo (6.9 vs 4.4, p=0.0023), indicating an effect of high outliers on the mean. Average HF severity was also improved in a dose-related manner, with greater reductions compared to placebo with the 2 higher NT-814 doses. Improvements in HF were accompanied by statistically significant benefits on sleep (assessed using the Insomnia Severity Index and Pittsburgh Sleep Quality Index), mood (measured using the Beck Depression Inventory), and all four domains of the MenQoL menopause-specific quality-of-life instrument. NT-814 was well-tolerated; most AEs were mild or moderate and there were no serious AEs related to treatment. Conclusions: NT-814, a once daily non-hormonal NK antagonist, at doses of 120 & 160 mg reduced the frequency and severity of VMS and significantly improved quality of life, mood and sleep, in postmenopausal women. NT-814 was well tolerated, with a safety profile that supports further evaluation in Phase 3 trials.

Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women

2009 ◽  
Vol 32 (2) ◽  
pp. 150-155 ◽  
Author(s):  
S. Basaria ◽  
A. Wisniewski ◽  
K. Dupree ◽  
T. Bruno ◽  
M. Y. Song ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Dose ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals Sleep disorders in menopausal women

2017 ◽  
Vol 6 (6) ◽  
pp. 2289
Author(s):  
Abha Singh ◽  
Abha Daharwal ◽  
Avinashi Kujur
Keyword(s):  
Sleep Disorders ◽  
Sleep Disturbances ◽  
Working Women ◽  
Psychosocial Problems ◽  
Study Group ◽  
Chi Square ◽  
Cross Sectional ◽  
Menopausal Women ◽  
Post Menopausal

Background: Sleep disturbance is one of frequent sign and symptom encountered in post-menopausal women. It affects the quality of the life and may lead to depression in some women. Objective of present study was to find out the prevalence of sleep disorder in post-menopausal womenMethods: Prospective study done on the post-menopausal women coming to Gynaecology OPD of Dr Bheem Rao Ambedkar Hospital, Raipur. This study was a prospective cross sectional observational study, conducted in the outpatient department of Obstetrics and Gynecology from 1st August 2016 to 31st January 2017. It included 500 women of postmenopausal age. A detail Performa was provided to assess sleep patterns and disorders associated with it. All the data was analysed using chi square testResults: The prevalence of sleep disturbances was 29.58%. Home makers were affected more in comparison to working women, 71,43% women had problems in initiating sleep. About 2/3rd women in the study group developed insomnia within 5 years of menopause, whereas 1/3rd took more than 7years to develop insomnia. Co morbidities were present in 48% women. Our women have mean age of menopause around 45 years.Conclusions: Sleep disorders are common, with prevalence of 29.5% in menopausal women in present study. It significantly causes psychosocial problems in women. There is need for it to be asked for and to be treated promptly.

A Study on Assessment of Quality of Life in Post Menopausal Women

2017 ◽  
Vol 10 (1) ◽  
pp. 15
Author(s):  
P. Maheshwari ◽  
B. Deepika ◽  
T. S. Shanmugarajan
Keyword(s):  
Quality Of Life ◽  
Menopausal Women ◽  
Post Menopausal
Sign in / Sign up

Export Citation Format

Share Document